GlassScriptPhysician profile
Christopher H Hsu
NPI 1336167618
$13,688.57
in general payments reported to CMS, 2019-2025
28 companies · $3,347 in 2025
The $3,347 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,755 · 2020: $758 · 2021: $1,642 · 2022: $2,111 · 2023: $1,495 · 2024: $2,580 · 2025: $3,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,361 · Education: $60.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,361.47 |
| Education | $60.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,360.53 | 2019-2025 | Clareon, Tryptyr, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $1,919.67 | 2022-2025 | Miebo, Xiidra, Envista Envy Iol |
| Amgen INC. | $1,497.17 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,489.03 | 2019-2021 | |
| Sight Sciences, INC. | $750.27 | 2019-2024 | Omni Surgical System |
| Novartis Pharmaceuticals Corporation | $586.86 | 2019-2023 | |
| Glaukos Corporation | $514.66 | 2023-2025 | Idosetr, Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $508.32 | 2020-2025 | |
| Horizon Therapeutics Plc | $489.97 | 2021-2023 | Tepezza |
| Oyster Point Pharma, INC. | $459.48 | 2022-2025 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $453.83 | 2021-2022 | |
| Allergan, INC. | $338.76 | 2019-2022 | |
| Dompe US, INC. | $330.82 | 2024-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $320.82 | 2019-2020 | |
| Shire North American Group INC | $251.63 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $228.61 | 2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $222.93 | 2022-2024 | Acthar |
| Eyevance Pharmaceuticals LLC | $138.83 | 2021-2022 | |
| Ocular Therapeutix, INC. | $129.54 | 2022 | |
| Rxsight INC | $125.00 | 2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Eyepoint US, INC. | $116.23 | 2021 | |
| Carl Zeiss Meditec, INC. | $112.99 | 2020-2021 | |
| Biotissue Holdings INC. | $102.01 | 2023 | |
| Abbvie INC. | $97.18 | 2022-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $86.19 | 2023 | Tecnis Iol |
| Biohaven Pharmaceutical Holding Company LTD. | $25.09 | 2022 | |
| Beaver-Visitec International, INC. | $17.92 | 2021 | |
| Halozyme INC | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.